Clinical trials: Helicobacter Pylori Eradication
Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.
- Trial name
- NCT03219723
- Testing
- Vonoprazan, Amoxicillin hydrate, Clarithromycin
- Where
- Japan
- Volunteers
- 560 people
- Sponsor
- Takeda
Helicobacter Pylori Infection
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
- Trial name
- NCT02547012
- Testing
- esomeprazole+amox+levo+tetra, esomeprazole+amox+levo
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Peptic Ulcer, Helicobacter Pylori Infection
Clarithromycin Resistant Tailored Therapy
1. Back ground Antibiotics resistance of Helicobacter pylori, especially to clarithromycin is one of the main causes of failure of eradication.
- Trial name
- NCT01453036
- Testing
- 23S rRNA point mutation test of Helicobacter pylori, UBT test & Gastroenterology with biopsy c silver stain
- Where
- South Korea
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Jin Il Kim
Helicobacter Pylori Infection
Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy
Reverse hybrid therapy achieves a higher eradication rate than bismuth quadruple therapy remained unanswered.
- Trial name
- NCT02547038
- Testing
- pantoprazole+bismuth+tetra+metro, (panto+amox+clar+metr)+(panto+amox)
- Where
- Taiwan
- Volunteers
- 352 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Infections
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
This study aims at evaluating efficacy and safety of quadruple therapy (bismuth, metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin, clarithromycin and omeprazole: OAC) in H. Pylori eradication.
- Trial name
- NCT00669955
- Testing
- Omeprazole, amoxicillin, clarithromycin, Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole
- Where
- United Kingdom
- Volunteers
- 440 people
- Sponsor
- Forest Laboratories
Stomach Ulcer
Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
To examine the efficacy of continued administration of rebamipide following bacteria eradication therapy in patients with H. pylori-positive active gastric ulcer in a placebo-controlled, double-blind study
- Trial name
- NCT00233389
- Testing
- Rebamipide
- Where
- Japan
- Volunteers
- 301 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01712711
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
Helicobacter Pylori Infection
High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
A phase 4 prospective, randomized, open-label clinical trial evaluating the efficacy of high dose dual therapy vs standard triple therapy in a diverse, urban New York City population.
- Trial name
- NCT05342532
- Testing
- Amoxicillin, Omeprazole, Clarithromycin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Helicobacter Pylori Infection
Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Addition of L. reuteri to the standard triple therapy improves H. Pylori treatment outcomes.
- Trial name
- NCT01593592
- Testing
- Lactobacillus reuteri, Omeprazole, Amoxicillin
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Zagazig University
Helicobacter Pylori Infection
Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori
This prospective controlled randomized open-label clinical trial is designed to determine the eradication rate of 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole regimen compared with 7-day standard triple therapy for…
- Trial name
- NCT01575899
- Testing
- Levofloxacin-Amox/clav., Clarithromycin-Amoxicillin
- Where
- Taiwan
- Volunteers
- 208 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Background: A progressive decrease in Helicobacter pylori eradication rates has been described over the years, so new combinations of antibiotics for treatment are needed.
- Trial name
- R+OCA (NCT03124199)
- Testing
- Rifaximin
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Helicobacter Pylori Infection
Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in…
- Trial name
- NCT01109381
- Testing
- GT08
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synergy Pharmaceuticals Pte. Ltd.
Helicobacter Pylori Infection
Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
According the Maastricht IV consensus report publish in the Gut 2012, bismuth containing quadruple therapy was suggested to be the first choice for eradication therapy of Helicobacter pylori in the area with high clarithromycin…
- Trial name
- NCT02541864
- Testing
- Bismuth quadruple therapy, Hybrid therapy
- Volunteers
- 330 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
1. To compare 10-day sequential therapy and 14-day modified bismuth quadruple therapy and to establish more effective first-line regimen for the eradication of Helicobacter pylori in Korea. 2. To evaluate the effect of H.
- Trial name
- NCT02159976
- Testing
- Pantoprazole, Amoxicillin, Clarithromycin
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
Reverse hybrid therapy is a one-step two-phase treatment for Helicobacter pylori infection with less cost than standard triple therapy.
- Trial name
- REHYTRI (NCT02359435)
- Testing
- Reverse hybrid therapy, Standard triple therapy
- Where
- Taiwan
- Volunteers
- 440 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
This phase Ⅰb/Ⅱa, single-center, randomized, open-label study was designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary Helicobacter Pylori eradication efficacy in asymptomatic subjects with…
- Trial name
- NCT06076681
- Testing
- TNP-2198, Rabeprazole Sodium, Amoxicillin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Helicobacter Infection
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
As increasing the antibiotics resistance, the effectiveness of traditional Helicobacter pylori (H. pylori) therapies has been declined coincidently. In this study, the investigators evaluated the efficacy of H.
- Trial name
- NCT02349685
- Testing
- H. pylori culture and antimicrobial susceptibility test, 14 day PBMT group, 14 day MEA group
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Parkinson's Disease, Helicobacter Infections
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Trial name
- NCT00664209
- Testing
- clartihromycin, amoxicillin, and omeprazole
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Helicobacter Pylori Infection
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth salts are not available.
- Trial name
- NCT02596620
- Testing
- Nexium, Amolin, Cravit
- Volunteers
- 164 people
- Sponsor
- Chang Gung Memorial Hospital
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01654549
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences